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ethanolamine; ECS, endocannabinoid system; EMT, endocannabinoid membrane 
transporter; FAAH, fatty acid amide hydrolase; MAGL, monoacylglycerol lipase; 
NAPE-PLD, N-acyl phosphatidylethanolamine-specific phospholipase D; OEA, 
oleoylethanolamide; PEA, palmitoylethanolamide; SG, sebaceous gland; SLP, 
sebaceous lipid production  
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ABSTRACT 
We have previously shown that i) endocannabinoids (eCB; e.g. anandamide [AEA]) are 
involved in the maintenance of homeostatic sebaceous lipid production (SLP) in human 
sebaceous glands (SG); and ii) eCB treatment dramatically increases SLP. Here, we 
aimed to investigate the expression of the major eCB synthesizing and degrading 
enzymes, and to study the effects of eCB uptake inhibitors on human SZ95 sebocytes, 
thus exploring the role of the putative eCB membrane transporter (EMT), which has 
been hypothesized to facilitate the cellular uptake and subsequent degradation of eCBs. 
We found that the major eCB synthesizing (NAPE-PLD, DAGLα and -β) and degrading 
(FAAH, MAGL) enzymes are expressed in SZ95 sebocytes, and also in SGs (except for 
DAGLα, whose staining was dubious in histological preparations). Interestingly, eCB 
uptake-inhibition with VDM11 induced a moderate increase in SLP, and also elevated 
the levels of various eCBs and related acylethanolamides. Finally, we found that 
VDM11 was able to interfere with the pro-inflammatory action of the Toll-like receptor 
4 activator lipopolysaccharide. 
Collectively, our data suggest that inhibition of eCB uptake exerts anti-inflammatory 
actions and elevates both SLP and eCB levels; thus, these inhibitors might be beneficial 
in cutaneous inflammatory conditions accompanied by dry skin.  
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INTRODUCTION 
Sebaceous glands (SG) are important players and regulators of the human skin 
homeostasis. Indeed, besides their obvious function, i.e. production of the lipid-rich 
sebum, and thereby contribution to the cutaneous lipid barrier and thermoregulation, 
they also play a role in the endocrine and immune systems of the skin, and serve as stem 
cell reservoirs as well (Dajnoki et al. 2017; Lupi 2008; Porter 2001; Tóth et al. 2011; 
Zouboulis et al. 2014; Zouboulis et al. 2008). Importantly, their clinical significance is 
also remarkably high, since overproduction and pathologically altered composition of 
sebum in seborrhea is a key step in the pathogenesis of acne, one of the most prevalent 
human skin diseases (Kurokawa et al. 2009; Tóth et al. 2011; Zouboulis et al. 2014; 
Zouboulis et al. 2008). On the other hand, lack of sufficient sebum production in 
adulthood may contribute to dry-skin syndrome, xerosis or even skin ageing and atopic 
dermatitis (AD) (Kim et al. 2014; Mischo et al. 2014; Shi et al. 2015; Zampeli et al. 
2012; Zouboulis and Boschnakow 2001). Moreover, unique composition of sebum is 
thought to play an important role in regulating the growth of the cutaneous microbiota 
by restricting the unwanted microbes, and promoting the preferred ones, thus making 
homeostatic SG functions important orchestrators of skin-microbiota cross-talk (Pappas 
2009). Hence, via the subsequent pathological alterations in the cutaneous microbiota, 
disorders of sebaceous lipid production (SLP) may contribute to the pathogenesis of 
several diseases, including AD (Shi et al. 2015). Therefore, a better understanding of 
(dys)regulation of SG biology, and identification of additional regulators of homeostatic 
SLP are clinically relevant topics of investigative dermatology. Unfortunately, human 
SGs are challenging to study, since primary sebocytes cannot be kept in culture for 
more than a few passages, and there are no adequate animal model systems to assess the 
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whole complexity of the human SG biology (Tóth et al. 2011; Zouboulis et al. 2014; 
Zouboulis et al. 2008). Therefore, within the scope of the current study, we used the 
human immortalized SZ95 sebocyte cell line (Zouboulis et al. 1999), which is a widely 
accepted model system to study human SG functions in vitro (Tóth et al. 2011; 
Zouboulis et al. 2014; Zouboulis et al. 2008). 
 
Interestingly, a growing body of evidence suggests that SGs are not only “innocent” 
targets of the complex cutaneous neuroendocrine system (Slominski 2005; Slominski 
and Wortsman 2000), but also its master regulators by producing several hormones and 
paracrine signal molecules (e.g. androgen hormones, corticotropin-releasing hormone, 
several adipokines, etc.) (Kovács et al. 2016; Tóth et al. 2011; Zouboulis et al. 2014; 
Zouboulis et al. 2008). Furthermore, we have previously shown that, besides the 
aforementioned regulators, human SGs are also important players in the 
endocannabinoid system (ECS) of the skin (Dobrosi et al. 2008; Oláh and Bíró 2017). 
 
The ECS is a complex signaling system, comprising endogenous ligands (i.e. the 
“endocannabinoids” [eCB], e.g. arachidonoylethanolamide [a.k.a. anandamide, AEA], 
2-arachidonoylglycerol [2-AG]), receptors (e.g. CB1 and CB2, etc.), as well as multiple 
enzymes involved in the synthesis (e.g. N-acyl phosphatidylethanolamine-specific 
phospholipase D [NAPE-PLD], diacylglycerol lipase [DAGL]-α and –β, etc.) and 
degradation (e.g. fatty acid amide hydrolase [FAAH], monoacylglycerol lipase 
[MAGL]) of the eCBs and related non-eCB mediators (such as monoacylglycerols and 
acylethanolamides, like palmitoylethanolamide [PEA], oleoylethanolamide [OEA], 
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etc.). Moreover, a putative eCB membrane transport mechanism (usually referred to as 
putative eCB membrane transporter [EMT]), postulated to facilitate cellular uptake and 
release of AEA and 2-AG also belongs to this system (Chicca et al. 2012; Ligresti et al. 
2016; Maccarrone 2017; Maccarrone et al. 2015; Nicolussi and Gertsch 2015; Solymosi 
and Köfalvi 2016). Importantly, we have previously shown that human SGs are capable 
of producing the major eCBs (namely AEA and 2-AG), and we could also demonstrate 
that (in line with the early data of the Ständer group) SGs express CB1 (mostly in 
differentiated cells) and CB2 receptors (predominantly in proliferating, basal layer 
sebocytes) (Dobrosi et al. 2008; Ständer et al. 2005). Moreover, we found that locally 
produced eCBs, acting through a CB2-coupled signaling pathway, are key players in the 
maintenance of the homeostatic SLP, since selective gene silencing of CB2 significantly 
reduced basal SLP of SZ95 sebocytes, whereas eCB-treatment of the cells led to greatly 
increased lipogenesis (Dobrosi et al. 2008). In this way, we provided to our knowledge 
previously unreported evidence that human SGs possess a functionally active ECS and 
that treatment of human sebocytes with exogenously administered AEA or 2-AG 
dramatically increases SLP. However, we did not have any data about either the 
expression of the enzyme apparatus involved in the synthesis and degradation of the 
eCBs, or the role of the local eCB tone created by these enzymes in human sebocytes. 
Thus, within the confines of the current, highly focused study, we aimed to explore the 
expression of the major members of the ECS in vitro in human sebocytes, as well as in 
situ in human skin, and we also wanted to investigate if pharmacological modulation of 
eCB homeostasis was indeed able to regulate SLP. 
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RESULTS 
Major enzymes of the eCB metabolism are expressed in cultured human sebocytes 
as well as in situ in human SGs 
First, by using human, immortalized SZ95 sebocytes, we investigated expression of the 
major enzymes involved in the synthesis and degradation of AEA (NAPE-PLD and 
FAAH, respectively) and 2-AG (DAGLα and –β and MAGL, respectively). We found 
that, irrespective of the confluence level of the cells, all the above mentioned enzymes 
were expressed in human sebocytes both at the mRNA (Q-PCR) and protein (Western 
blot) levels (Supplementary Figure S1a-d). In order to further confirm these results, 
we also investigated their expression in human skin samples (appropriately labeled 
positive controls are shown on Supplementary Figure S2). Importantly, with the sole 
exception of DAGLα, which exhibited questionable expression when compared to the 
endogenous positive control sweat glands (Czifra et al. 2012), our findings nicely 
confirmed our in vitro data about the expression of the above enzymes in human SGs in 
situ (Figure 1). 
 
Sebocytes exhibit a pharmacologically inhibitable eCB uptake process 
Next, we assessed if pharmacologically inhibitable AEA uptake by the putative EMT 
(Chicca et al. 2012; Nicolussi and Gertsch 2015) was observable in these cells. By 
monitoring the uptake of radiolabeled [3H]AEA by the cells, we found that acute 
inhibition (15 min, 10 µM) of AEA cellular uptake using the reference eCB transport 
inhibitor UCM707 (López-Rodríguez et al. 2003; Rau et al. 2016) was able to 
significantly alter the eCB uptake process. Indeed, UCM707 reduced the intracellular 
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[3H]AEA signal, which was accompanied by a significant increase in the extracellular 
[3H]AEA levels compared to vehicle control. As a consequence of [3H]AEA uptake 
inhibition, the overall hydrolysis of [3H]AEA by FAAH to arachidonic acid and 
[3H]ethanolamine ([3H]EtNH2) was reduced (Figure 2a). Theoretically, a decrease of 
[3H]AEA uptake and [3H]EtNH2 levels could be explained not only by the inhibition of 
the eCB transport process, but also by non-specific inhibition of FAAH resulting in a 
reduced driving force for [3H]AEA uptake (Chicca et al. 2012; Nicolussi et al. 2014a). 
To exclude this possibility, we assessed how two different EMT-inhibitors (namely 
UCM707 and VDM11; both widely used to abrogate cellular uptake of eCBs) (De 
Petrocellis et al. 2000; López-Rodríguez et al. 2003), influence FAAH activity in SZ95 
sebocytes, in comparison with the reference FAAH-inhibitor URB597 (Mor et al. 
2004). Importantly, we found that SZ95 sebocytes exhibit very low constitutive FAAH 
activity (2.32±0.25 pmol/min/mg protein; n=10), and that, unlike URB597, neither 
UCM707, nor VDM11 exerted substantial FAAH-inhibition (IC50 values were above 25 
µM for both EMT-inhibitors, whereas IC50 of URB597 was below 100 nM) 
(Supplementary Table S1). Taken together, these findings suggest that in human 
sebocytes eCB uptake can be inhibited by VDM11 most likely through a FAAH 
independent manner. 
 
EMT plays a role in the degradation of eCBs in human sebocytes 
Next, we investigated the eCB transport process using one of the aforementioned EMT-
inhibitors, VDM11 (De Petrocellis et al. 2000). Cells were treated with this compound 
or vehicle for 24 hours and eCB content of the samples was analyzed by LC-MS. We 
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found that VDM11 treatment significantly increased AEA content of the samples 
(Figure 2b), whereas elevation of 2-AG concentration did not reach statistical 
significance (Figure 2c). Besides the two major eCBs, we also investigated the 
presence and potential alterations of two ECS-related acylethanolamides, i.e. PEA and 
OEA. Interestingly, we found that treatment by VDM11 tended to increase PEA, and 
significantly elevated OEA concentrations (Figure 2d-e). Collectively, these data 
provided evidence that administration of VDM11 can increase the levels of certain 
eCBs and eCB-like mediators in human sebocytes. These results hold out the promise 
that VDM11 might therefore promote homeostatic eCB and eCB-like mediator 
signaling in these cells. 
 
Administration of eCB membrane transport inhibitors mimics lipogenic actions of 
direct eCB-treatment, whereas selective FAAH-inhibition does not influence SLP 
It is well-described that direct eCB-treatment of the sebocytes results in a dramatically 
increased SLP (Dobrosi et al. 2008; Oláh et al. 2016b; Oláh et al. 2014). Thus, next we 
wanted to assess how treatment with eCB uptake inhibitors influences SG’s functions. 
Using non-cytotoxic concentrations (determined by MTT-assay; Supplementary 
Figure S3) of the aforementioned VDM11, we explored its effect on SLP. By using 
fluorescent Nile Red staining, we found that its low micromolar concentrations induced 
a moderate, but significant increase in the SLP following 48-hr treatments (Figure 3a). 
Importantly, repetition of the experiment by using AM404 (another well-known AEA 
uptake inhibitor) (Beltramo et al. 1997; Nicolussi and Gertsch 2015) yielded very 
similar results (Supplementary Figure S4a-b). Intriguingly, although both VDM11 
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and AM404 mimicked the lipogenic actions of the prototypic eCB AEA (Dobrosi et al. 
2008), their efficiencies at elevating SLP were far exceeded by direct AEA-treatment 
(Figure 3a). 
 
As discussed above, several lines of evidence demonstrate that eCB uptake inhibitors 
may concentration-dependently inhibit not only the putative EMT, but FAAH as well 
(Beltramo et al. 1997; Chicca et al. 2017; Nicolussi and Gertsch 2015). Although our 
current measurements on sebocytes’ FAAH-activity already provided strong evidence 
that i) SZ95 sebocytes exhibit very low constitutive FAAH activity; and ii) in SZ95 
sebocytes, both UCM707 and VDM11 can be used at 10 µM without the risk of having 
substantial impact on FAAH activity (Supplementary Table S1), we also intended to 
investigate biological effects of the selective reference FAAH-inhibitor URB597 (Mor 
et al. 2004). Interestingly, we found that administration of URB597 led to different cell 
physiology outcome than application of VDM11 and AM404. Indeed, our data showed 
that non-cytotoxic concentrations (MTT-assay; Supplementary Figure S5a) of 
URB597 did not influence SLP (48-hr treatments; Supplementary Figure S5b) as 
compared to the vehicle control group, indicating that abrogation of eCB uptake, but not 
inhibition of their FAAH-mediated intracellular degradation, leads to the elevation of 
the SLP. It is also important to note that such lack of effect by URB597 can most likely 
be ascribed to the aforementioned very low levels of FAAH activity in SZ95 sebocytes. 
 
Lipogenic action of direct AEA treatment is not further increased by co-
administration of VDM11 
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Next, we intended to assess how co-administration of AEA and VDM11 affect SLP. 
Interestingly, we found that VDM11 was unable to further promote the AEA-induced, 
already elevated SLP (Supplementary Figure S6) of human sebocytes, suggesting that 
the pro-lipogenic eCB signaling activated by 30 µM AEA is exhaustive, and has no 
further “reserve capacity”. 
 
Up to 10 µM, VDM11 does not induce apoptosis of human sebocytes 
Elevation of SLP is the hallmark of sebocyte differentiation, which is usually followed 
by programmed cell death (Dobrosi et al. 2008; Fischer et al. 2017; Tóth et al. 2011; 
Zouboulis et al. 2014; Zouboulis et al. 2008). Since VDM11 was shown to moderately 
promote SLP (Figure 3a; Supplementary Figure S4b), we also wanted to know if it 
induced early apoptotic processes. Importantly, we found that, although the most 
effective lipogenic concentration of VDM11 tended to decrease mitochondrial 
membrane potential in course of 48-hr treatments (Supplementary Figure S7), this did 
not reach the level of significance, suggesting that within the studied time-frame, it may 
indeed be devoid of obvious pro-apoptotic effects. 
 
VDM11 suppresses lipopolysaccharide (LPS)-induced pro-inflammatory cytokine 
expression of human sebocytes 
From a clinical point-of-view, induction of a moderate (not seborrheic or acnegenic) 
increase in the homeostatic SLP would be highly desirable in the treatment of skin 
dryness (Kim et al. 2014; Mischo et al. 2014; Shi et al. 2015; Zampeli et al. 2012; 
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Zouboulis and Boschnakow 2001). Thus, our above results suggest that administration 
of VDM11 (and probably other EMT-inhibitors too) may possess beneficial effects in 
such conditions. Considering that skin dryness is frequently accompanied by cutaneous 
inflammation (e.g. in the case of AD) (Peng and Novak 2015; Sugiura et al. 2014), we 
finally investigated how VDM11 affects immune properties of human sebocytes. To 
this end, we applied lipopolysaccharide (LPS; 5 µg/ml; 3-hr treatments) (Oláh et al. 
2016b) to induce pro-inflammatory response. Importantly, co-administration of VDM11 
(10 µM) efficiently suppressed LPS-induced expression of interleukin (IL)-1α, IL-1β, 
IL-6, IL-8 and tumor necrosis factor (TNF)-α by human sebocytes (Q-PCR; Figure 3b). 
Moreover, as revealed by subsequent ELISA analyses, VDM11 treatment significantly 
suppressed LPS-induced release of IL-6, and led to only a minor, non-significant 
decrease in IL-8 secretion (24-hr treatments; Figure 3c). Concentrations of the other 
three cytokines were below (TNFα) or around (IL-1α and IL-1β) the detection limit of 
the respective assays (data not shown). 
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DISCUSSION 
Skin dryness and the often accompanying overwhelming cutaneous inflammatory 
processes (e.g. in AD, etc.) can dramatically impair quality of life of many patients. On 
the other hand, appropriate moisturization and emollient treatment of the skin can 
alleviate symptoms, and, in some cases, they are even able to prevent the onset of AD 
(Hoppe et al. 2015; Oláh et al. 2017; Sawatzky et al. 2016; Sugiura et al. 2014). 
Although inappropriate epidermal ceramide production is thought to be the most 
important player in these processes, a growing body of evidence supports now the 
concept that dysregulation of SGs functions and the subsequent alterations in the SLP 
are also fundamental. Indeed, sebostasis, SG hypoplasia and reduced SLP (with 
pathologically reduced squalene and wax ester content) were shown to occur in AD, and 
an inverse correlation between the prevalence of acne and AD (the former characterized 
by increased, whereas the latter by decreased sebum production) was also observed (Shi 
et al. 2015). These findings, together with those ones demonstrating that sebaceous 
lipids are important regulators of the growth of cutaneous microbiota (Pappas 2009) 
collectively suggest that controlled, moderate “sebostimulation” (ideally without 
altering the physiological composition of the sebum) may be beneficial in diseases 
characterized by skin dryness. 
 
The eCB signaling, a recently emerging, new regulator of cutaneous biology 
(Maccarrone et al. 2015), appears to be a very promising subject of study in this field. 
Indeed, we have previously shown that i) human sebocytes are able to produce the two 
major eCBs (AEA and 2-AG); ii) CB2 receptor-coupled signaling contributes to the 
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maintenance of homeostatic SLP; and iii) direct AEA or 2-AG treatments dramatically 
increase lipogenesis (Dobrosi et al. 2008). On the other hand, (-)-cannabidiol, as well as 
several further non-psychotropic phytocannabinoids (e.g. (-)-∆9-tetrahydrocannabivarin) 
were shown to normalize arachidonic acid- and other mediators-induced excessive lipid 
synthesis, and exerted complex (combined lipostatic, anti-proliferative and anti-
inflammatory) anti-acne effects, whereas others (namely (-)-cannabigerol and (-)-
cannabigerovarin) were able to slightly, but significantly promote SLP (Oláh et al. 
2016b; Oláh et al. 2014). Hence, in the current study we aimed to unveil yet hidden 
aspects of the ECS of human sebocytes. 
 
Here we provide evidence that major members of the ECS (i.e. NAPE-PLD, DAGLα 
and –β, MAGL and FAAH) are expressed both in vitro in human sebocytes 
(Supplementary Figure S1a-d), and (with the sole exception of DAGLα, which 
exhibited dubious immunostaining pattern) also in situ in SGs of the human skin 
(Figure 1), which nicely confirms the available murine data of MAGL (Ma et al. 2011) 
and FAAH (Wohlman et al. 2016) expression in SGs. Moreover, besides the expression 
of the enzymes, we could also show that eCB transport is functionally active and 
pharmacologically inhibitable in human sebocytes (Figure 2a). This process is more 
likely to be involved in (re-)uptake/degradation rather than synthesis/release of the 
eCBs, since VDM11 (10 µM for 24 hours) significantly elevated AEA level in the 
samples, and tended to increase 2-AG concentration too. Interestingly, although this 
compound was proven to only negligibly alter FAAH-activity in sebocytes 
(Supplementary Table S1), we also observed a significant elevation in OEA levels, 
and a tendency towards increase in PEA concentrations (Figure 2b-e). 
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Next, we tested the effects on the viability, lipid synthesis and immune responses of 
human sebocytes. We found that non-cytotoxic concentrations of VDM11 and AM404 
(Supplementary Figures S3, S4a and S7) induced a moderate, but significant increase 
in the SLP (Figure 3a; Supplementary Figure S4b), and that VDM11 interfered with 
the pro-inflammatory effects of LPS (Figure 3b-c). It is noteworthy that certain 
sebocyte-derived cytokines (e.g. IL-6) can induce differentiation of CD4+/CD45RA+ 
naïve T cells into T helper (Th)17 cells (Mattii et al. 2017), further supporting the 
concept that dysregulation of sebocyte biology can contribute not only to the 
development of acne, but also to other (partly) Th17-driven inflammatory dermatoses, 
e.g. AD or psoriasis. Thus, the suppression of IL-6 expression and release that we have 
demonstrated here (Figure 3b-c) is likely to be clinically relevant, and promises to be 
beneficial in such conditions. 
 
Collectively, these findings strongly suggest that abrogation of sebocytes’ eCB 
degradation, and the subsequent elevation of the “eCB-tone” promotes SLP. However, 
quite unexpectedly, by using the FAAH inhibitor URB597, we found that, albeit being 
successful in suppressing FAAH-activity of the sebocytes (Supplementary Table S1) it 
had no effect on SLP (Supplementary Figure S5). Explanation of this unexpected 
finding remains to be unveiled in future, targeted studies, but may lie in the fact that 
relatively low levels of FAAH activity (measured as the capability of cell membranes to 
hydrolyze radiolabeled AEA) was detected in SZ95 sebocytes. Further possible 
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interpretations about the possible underlying mechanisms are presented in the 
Supplementary Discussion section 1. 
 
As discussed above, a moderate (i.e. not excessive, seborrheic/acnegenic) elevation of 
the physiological SLP would be highly desirable in the management of diseases 
accompanied by skin dryness (e.g. AD) (Pappas 2009; Shi et al. 2015). The fact that the 
lipogenic effect of VDM11 was far weaker than the ones usually seen upon direct AEA 
(Figure 3a), or other lipogenic (e.g. 2-AG, arachidonic acid and linoleic 
acid+testosterone) treatments (Dobrosi et al. 2008; Géczy et al. 2012; Oláh et al. 2016b; 
Oláh et al. 2014), together with the here reported anti-inflammatory effect (Figure 3b-c) 
indicates that VDM11 (and maybe other eCB transport inhibitors) may be beneficial in 
treating such diseases. Obviously, however, the exact impact of VDM11 treatment on 
the sebaceous lipidome must be thoroughly investigated in future specific studies in 
order to exclude the possibility of its potential “acnegenic” transformation. 
 
It is noteworthy that anti-inflammatory effects of elevated eCB-tone are not 
unprecedented either in murine or in human skin. Indeed, since the groundbreaking 
work of Karsak and her co-workers, many other studies showed that the homeostatic 
ECS is one of the master regulators of cutaneous immune responses, keeping under 
control local allergic and inflammatory processes (Karsak et al. 2007; Oláh et al. 
2016a). 
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Moreover, the fact that VDM11 could significantly increase OEA, and tended to elevate 
PEA levels (Figure 2d-e) highlights the possibility that SGs may contribute to the 
cutaneous PEA and OEA metabolism and supply of their local micromilieu with these 
pleiotropic anti-inflammatory molecules (Facci et al. 1995; Impellizzeri et al. 2015; 
Pontis et al. 2016; Yang et al. 2016). Based on these data, there is a possibility that SG 
hypoplasia and hypofunction observed in AD (Shi et al. 2015) may be accompanied not 
only by reduced sebum production, but also by impaired PEA (and/or OEA) supply, 
which might contribute to the development and worsening of atopic inflammation. 
Considering that a PEA containing cream was recently shown to efficiently alleviate 
symptoms of AD patients (“ATOPA study”) (Eberlein et al. 2008), clinical studies are 
urgently invited to explore the possible role of SG hypoplasia-derived putative 
PEA/OEA-deficiency in the development of AD symptoms. Further speculations about 
the possible role and targets of PEA and OEA are mentioned in the Supplementary 
Discussion section 2. 
 
Collectively, our findings demonstrate that i) human sebocytes express the most 
important enzymes involved in eCB and eCB-like mediator metabolism; ii) are involved 
in the cutaneous metabolism of PEA and OEA; and that VDM11 iii) increases or tends 
to increase the levels of eCBs and related acylethanolamides; (iv) induces a moderate 
increase in SLP; and (v) remarkable anti-inflammatory actions in human sebocytes 
(summarized in Supplementary Figure S8). Thus, human SGs may be important in 
regulating the supply of key eCBs and related acylethanolamides to their tissue 
microenvironment, and targeting the ECS holds out promise to control cutaneous 
inflammation. All in all, our data should encourage the exploitation of selected, SG-
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targeting ECS-modulators in appropriate clinical trials, to alleviate symptoms of 
cutaneous diseases (e.g. AD) characterized by skin dryness and inflammation. 
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MATERIALS AND METHODS 
Detailed description of the applied materials and methods can be found in the 
Supplementary Methods and Methods section. Briefly, lipid synthesis was 
investigated by fluorescent Nile Red staining, viability and cell death was assessed by 
MTT-assay and combined fluorescent DilC1(5)-SYTOX Green labeling, respectively. 
Gene expression was studied by Q-PCR (mRNA level), ELISA, Western blot and 
immunohistochemistry (protein level). The uptake of AEA into cells was determined by 
measuring the cellular uptake of radiolabeled AEA as described before (Nicolussi et al. 
2014b; Nicolussi et al. 2014a), whereas levels of the eCBs were quantified by isotope 
dilution-liquid chromatography coupled to single quadrupole mass spectrometric (LC-
MS) analysis (Marsicano et al. 2002), and FAAH-activity was determined according to 
our previously established and optimized protocol (Ortar et al., 2003). Data were 
analyzed by Origin Pro Plus 6.0 software (Microcal, Northampton, MA, USA), using 
Student’s two tailed, unpaired t-test and P<0.05 values were regarded as significant 
differences. Graphs were plotted by using Origin Pro Plus 6.0 software (Microcal). 
Primary human material was collected after obtaining written informed consent, 
adhering to Helsinki Declaration, and after obtaining Institutional Research Ethics 
Committee’s and Government Office for Hajdú-Bihar County’s permission (document 
IDs: IX-R-052/01396-2/2012, IF-12817/2015, IF-1647/2016, IF-778-5/2017). 
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FIGURE LEGENDS 
Figure 1 Major enzymes of the endocannabinoid metabolism are expressed in human 
sebaceous glands in situ 
Immunohistochemistry of human skin sections was performed as described in the 
Supplementary Methods section. Specific immunopositivity was visualized by 3,3’-
diaminobenzidine (DAB; brown color), whereas nuclei were counterstained by 
hematoxylin (blue color). Original magnifications: 100x (left column), 400x (middle 
and right columns); scale bars: 200 µm (left column) and 50 µm (middle and right 
columns). Arrows indicate sweat glands (endogenous positive control for DAGLα), 
whereas arrowheads mark sebaceous glands on the same image. Negative controls (right 
column) were obtained by omitting the primary antibody in all cases. DAGL: 
diacylglycerol lipase; FAAH: fatty acid amide hydrolase; MAGL: monoacylglycerol 
lipase; NAPE-PLD: N-acyl phosphatidylethanolamine-specific phospholipase D. 
 
Figure 2 Effects of the inhibitors of the putative endocannabinoid membrane 
transporter in human sebocytes 
(a) AEA transport measurement. Cells were treated with the reference AEA uptake 
inhibitor UCM707 or vehicle for 15 min, and intra- and extracellular amounts of 
radiolabeled AEA or EtNH2 were detected as described in the Supplementary Methods 
section. Results are expressed in the percentage of the vehicle control (100%, solid line) 
as mean±SEM of three independent experiments, each run in triplicate. (b-e) AEA, 2-
AG, PEA and OEA determination of the samples (i.e. cells and their supernatants 
together) was performed as described in the Supplementary Methods section. Results 
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are expressed as mean±SEM of 3-4 independent cultures. *, ** and *** mark 
significant (P<0.05, 0.01 or 0.001, respectively) differences compared to the vehicle 
control. n.s.: not significant difference. 2-AG: 2-arachidonoylglycerol; AEA: N-
arachidonoylethanolamine (anandamide); EMT: (putative) endocannabinoid membrane 
transporter; OEA: oleoylethanolamide; PEA: palmitoylethanolamide; UCM707 and 
VDM11: EMT-inhibitors. 
 
Figure 3 Non-cytotoxic concentrations of VDM11 moderately, but significantly 
increase sebaceous lipid synthesis, and exert remarkable anti-inflammatory effects 
(a) Sebaceous lipid production of SZ95 sebocytes was assessed by Nile Red staining 
following 48-hr treatments. Results are expressed in the percentage of the vehicle 
control (100%, solid line) as mean±SEM of four independent determinations. One 
additional experiment yielded similar results. ** and *** mark significant (P<0.01 and 
0.001, respectively) differences compared to the vehicle control. ###P<0.001. n.s.: not 
significant difference compared to the vehicle control. (b) Q-PCR. IL-1α, IL-1β, IL-6, 
IL-8 and TNF-α mRNA expressions were determined following 3-hr LPS-treatment 
with or without VDM11. Data are presented by using ∆∆CT method regarding 18S 
RNA-normalized mRNA expressions of the vehicle control as 1 (solid line). Data are 
expressed as mean±SD of three determinations. One additional experiment yielded 
similar results. ** and ***P<0.01 and 0.001, respectively, as indicated. (c) ELISA. IL-6 
and IL-8 content of the sebocyte supernatants was determined following 24-hr LPS-
treatment with or without VDM11. Data are expressed as mean±SD of three 
determinations. Two additional experiments yielded similar results. ***P<0.001, as 
indicated. n.s.: not significant difference. AEA: N-arachidonoylethanolamine 
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(anandamide); EMT: endocannabinoid membrane transporter; IL: interleukin; LPS: 
lipopolysaccharide; TNF: tumor necrosis factor; VDM11: EMT-inhibitor. 
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